Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the publication of company-sponsored research in the European Journal of Pain. The article, titled ‘Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation’, highlights results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship Program. “Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the ‘holy grails’ in the field of analgesia,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.” The study results, which can be reviewed at http://nnw.fm/lRwM5, suggest that peripheral application of cannabinoids targeting the natural endocannabinoid receptor system may provide a valuable approach in treating severe pain.
To view the full press release, visit http://nnw.fm/xdW5Q
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
More from HempNewsBreaks
SeeThruEquity Initiates Coverage on Alternate Health Corp. (AHGIF)
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, CO
www.hempwire.com
303.498.7722 Office
[email protected]
